Dermatologic Agents

http://evolve.elsevier.com/Edmunds/NP/

Class	Subclass	Generic Name	Trade Name
TOPICAL CORTICOSTEROIDS (SEE TABLE 13-2)
Immunosuppressive drugs		pimecrolimus	Elidel
		tacrolimus	Protopic
ANTIINFECTIVES
Topical antibiotics		mupirocin	Bactroban
		bacitracin	Bacitracin, Baciguent
		erythromycin	Akne-mycin
		gentamicin	Garamycin
		nystatin	Mycostatin
		polymyxin B sulfate	In Polysporin, Neosporin
		retapamulin	Altabax
Topical antifungals	Azoles	clotrimazole	Lotrimin, Mycelex, Lotrisone
		econazole	Spectazole
		ketoconazole	Nizoral
		miconazole	Monistat-Derm
		oxiconazole	Oxistat
		sertaconazole	Ertaczo
		sulconazole	Exelderm
	Allylamine/benzylamine derivatives	butenafine	Mentax
		naftifine	Naftin
		terbinafine	Lamisil
	Hydroxypyridones	ciclopirox	Penlac, Loprox
	Others	nystatin	Nystatin, Mycostatin
		haloprogin	Halotex
		tolnaftate	Tinactin
		selenium sulfide lotion	2.5% Selsun
Topical antivirals		acyclovir	Zovirax
		penciclovir	Denavir
		docosanol	Abrevia
Scabicides/pediculicides		crotamiton	Eurax
		ivermectin	Stromectol, Sklice
		malathion	Ovide
		permethrin	Elimite, Nix
		lindane	Kwell
		spinosad	Natroba
ACNE PREPARATIONS
Antibacterial/keratolytic		benzoyl peroxide	Benzac (prescription), many brands OTC
		metronidazole	MetroGel
		clindamycin	Cleocin-T
Topical retinoid		tretinoin	Retin-A, Avita
Oral retinoid		isotretinoin	Generic
LOCAL ANESTHETICS	Short acting	procaine HCl	Novocain
		chloroprocaine	Nesacaine
	Intermediate acting	lidocaine HCl	Xylocaine
		mepivacaine HCl	Carbocaine HCl
		prilocaine HCl	Citanest
	Long acting	bupivacaine HCl	Marcaine, Sensorcaine,
		etidocaine	Exparel LA
		tetracaine HCl	Duranest
			Pontocaine HCl

Top 100 drug.

INDICATIONS

Topical Corticosteroids

• Inflammatory and pruritic dermatoses that are responsive to corticosteroids, such as psoriasis, eczema, contact dermatitis, and many other dermatoses

Topical Antiinfectives (Antibiotics)

• Infection prophylaxis in minor cuts, wounds, burns, and skin abrasions; aid to healing

• Treatment of superficial infections of the skin caused by susceptible organisms amenable to local treatment

Antifungals

• Superficial fungal infections (see Table 13-4)

Scabicides/pediculicides

• See Table 13-5 for indications.

Topical and Oral Acne Preparations

• Acne vulgaris

Local Anesthetics

• Local anesthetics are indicated for a variety of uses, which include minor surgical procedures, suturing, and relief of itching or pain from wounds, burns, and/or hemorrhoids.

• Local anesthesia does not depress the patient’s level of consciousness, which makes its use much safer than general anesthesia. Local anesthetics may be applied as a powder, gel, lotion, ointment, spray, or injection into a small area. If a larger area is required for anesthesia, a nerve trunk (epidural, spinal) or a single nerve may be injected to provide for regional anesthesia. This discussion is not intended as a complete presentation but rather as a brief overview of common local anesthetics used in primary care.

• Local anesthetics may be combined with vasoconstrictors (epinephrine) to prolong action by decreasing systemic absorption. However, at the ends of arteries, such as in the fingers, toes, penis, and nose, vasoconstrictors are not safe for use. In those areas, gangrene may develop because of severe vasoconstriction.

• A number of local agents are used safely on mucous membranes, ulcers, or wounds. If agents are applied to the oral cavity, however, the patient may have difficulty swallowing. Therefore, food should be withheld for at least 1 hour to prevent aspiration. Use with caution in areas of inflammation.

• Do not use if solutions are discolored or if they contain precipitants. If the solution does not contain a preservative, it must be discarded after opening. Because some situations of severe anaphylaxis have resulted from the use of local anesthetics, have resuscitation equipment on hand before use or emergency backup plans when any anesthetic is used. Obtain the patient’s prior history of local anesthetic use before administration. Patient or guardian should sign a permission form before consenting to any procedure involving a local anesthetic.

This chapter discusses preparations used for skin, nail, and hair problems. These preparations are used for an extremely large array of dermatologic problems. See each section for more specific indications. General issues in topical medications are discussed; then corticosteroids, antiinfectives, acne medications, and local anesthesia are discussed, each in a separate section. The purpose of this chapter is to discuss the most common of the various available agents. It does not attempt to address all of the preparations or the myriad indications for these agents. This chapter focuses on the topical use of these products. See appropriate chapters for more information about drugs from specific drug categories.

Therapeutic Overview of Dermatologic Agents

Anatomy and Physiology

The primary function of the skin is as a barrier. It functions to protect and thermoregulate. The skin is involved in the immune response, biochemical synthesis, and sensory detection. The skin’s barrier function is compromised when the skin has been damaged or when inflammation is present.

The skin, the largest organ of the body, consists of three distinct layers: epidermis, dermis, and subcutaneous tissue (Figure 13-1). The epidermis is the outer layer of the skin. The thickness of the epidermis ranges from 0.05 mm on the eyelids to 1.5 mm on the palms and soles. Five layers make up the epidermis. Basal cells form a single layer of cells that make up the innermost layer of the epidermis. These basal cells divide to form keratinocytes. The other layers are formed as keratinocytes change until they migrate to the outer layer to become the major component of the stratum corneum. The stratum corneum provides protection to the skin by acting as a barrier. The thicker the epidermis, the greater the barrier protection.

FIGURE 13-1 Structure of the skin. From Thibodeau GA, Patton KT: Anatomy and physiology, ed 7, St Louis, 2010, Mosby

Subcutaneous tissue is the deepest layer. Distribution is dependent on sex characteristics. Age, heredity, and caloric intake also influence distribution. The subcutaneous tissue provides padding and insulation to the underlying structures.

New research has suggested that tattoo inks may include carcinogens (such as benzopyrene) and hormone disruptors (such as dibutyl phthalate, which can mimic estrogen or disrupt testosterone), and their injections into skin with small needles are linked to allergic rashes, chronic skin reactions, infection, and inflammation from sun exposure. The Food and Drug Administration has launched new studies to investigate the long-term safety of the inks, including what happens when they break down in the body or interact with light. It appears that when skin cells containing ink are killed by sunlight or laser light, the ink breakdown products could spread throughout the body. Research already has shown that tattoo inks migrate into people’s lymph nodes, but the connection of tattoo inks to malignancies such as melanoma, basal cell carcinomas, squamous cell carcinomas, and keratoacanthomas is not clear. The long-term health risks posed by tattoo inks are unknown. There may be potential effects on fetuses and infants—for example, in infant boys, feminization of the reproductive tract may occur with phthalate exposure.

Pathophysiology

Three types of primary skin lesions have been identified: the macule, the papule, and the vesicle. Variations of these lesions are named according to the size of the lesion. Secondary lesions include erosion, ulcer, fissure, crust, lichenification, atrophy, excoriation, scar, and keloid.

When one is describing a skin lesion, it is important to accurately name the type of lesion by using this terminology. Location on the body and pattern of distribution are important. Timing and course should include whether the onset was acute or insidious. Also, the presence of any systemic signs and symptoms should be noted.

Mechanism of Action

Topicals work by being absorbed into the skin. Their effect is local. The specific mechanisms of action are discussed in each separate section. Topical preparations are available in a bewildering array of products, including many combination products, corticosteroid products of different strengths, and antiinfectives of every kind. The primary care provider should become familiar with a few products and treatment measures rather than trying to master the complete array. Superficial skin infections and acne are commonly treated in primary care. If the patient does not respond to standard care, he is referred to a dermatologist. Primary care providers should be able to identify suspicious lesions and refer patients promptly to dermatology; such patients frequently require surgical treatment.

Where applicable, specific information regarding standard guidelines, evidence-based recommendations, cardinal points of treatment, pharmacologic treatment, and nonpharmacologic treatment is provided later in the chapter.

Topical therapy is unique because the skin is directly accessible for both diagnosis and therapy. Drugs used to treat skin problems can be applied directly to the site. All topical agents can also be absorbed systemically. Consider the adverse effects of the systemic medication when you are ordering topical agents.

Factors that affect the extent of drug absorption into the skin include the status of the skin, the characteristics of the drug, and the characteristics of the administration vehicle. Absorption is increased when the skin is broken or inflamed. In addition, absorption increases in cases in which skin integrity is compromised or the skin is thinner. Because of the vascular composition of the skin, mucous membranes absorb medication in high concentrations. The vehicle or base affects percutaneous absorption (Table 13-1). The vehicle may hydrate the outer layer of skin by preventing water loss. With improved hydration, the absorption of medication and the depth of penetration are enhanced.

TABLE 13-1

Characteristics of Vehicle of Selected Topical Products

	Creams	Ointments	Gels	Solutions and Lotions	Aerosols
Base	Mixture of several different organic oils and water	Mixture of a limited number of organic compounds consisting primarily of petroleum jelly with little or no water	Greaseless mixtures of propylene glycol, water, and alcohol	Alcohol, water, and some chemicals	Drug suspended in a base and delivered via a propellant (e.g., isobutane, propane)
Color	White, somewhat greasy	Translucent, greasy feeling persists on skin	Clear with a gelatinous consistency	Clear or milky
Versatility	Most frequent base prescribed, used on nearly all body areas, especially useful in the intertriginous areas (e.g., groin, genital area, axillae)	Greater penetration, useful for drier lesions, enhanced potency	Unpleasant sticky feeling, may be irritating	Most useful for scalp because it penetrates the hair shaft	Useful for applying to scalp via a long probe attached to a can
Miscellaneous	Cosmetically more acceptable; can be drying after prolonged use, best used for acute exfoliative dermatitis	Too occlusive for acute exudative eczematous inflammation; too occlusive for intertriginous areas	Alcohol gels feel cool and are drying; useful in acute exudative inflammation (e.g., poison ivy); nonalcoholic gels are more lubricating and can be useful in drying scalp lesions; useful in scalp areas because other vehicles mat hair	May be drying and irritating when used in intertriginous areas	Convenient for patients who lack mobility and have difficulty in reaching lower legs; useful for moist lesions (e.g., poison ivy)

Absorption of topical medications is slow and incomplete compared with drugs given orally. For optimal absorption, apply them to moist skin either immediately after bathing or after wet soaks.

Prescribing the appropriate amount of topical medication is important. Too large a tube may be very costly to the patient, yet a small tube may not include enough medication to cover the entire area. To estimate the amount that should be prescribed, the rule of nines can be used (Figure 13-2).

FIGURE 13-2 Rule of nines to calculate quantity of medication to be dispensed. From Habif TP: *Clinical dermatology*, ed 4, St Louis, 2004, Mosby.

3. Apply topical medications with long, downward strokes to the affected areas. Avoid back-and-forth strokes because they may cause irritation of the hair follicles.

4. A tongue blade may be used for the application of topicals in a paste form.

5. Make sure to wash hands after application.

Topical Corticosteroids

For a listing, see Table 13-2.

TABLE 13-2

Topical Corticosteroids Ranked by Potency ∗

Group	Generic Name	Dosage Form	Strength (%)	Brand Name
I, Very High	clobetasol propionate	Cream, ointment	0.05	Temovate, generic
	betamethasone dipropionate	Ointment	0.05	Diprosone, generic
	diflorasone diacetate	Ointment	0.05	Psorcon E, generic
	halobetasol propionate	Cream, ointment	0.05	Ultravate, generic
II, High	amcinonide	Cream, lotion, ointment	0.1	Amcinonide
	betamethasone dipropionate	Cream	0.05	Diprosone
	betamethasone valerate	Ointment	0.1	Valisone
	desoximetasone	Cream, ointment	0.25	Topicort, generic
	diflorasone diacetate	Gel	0.05	Psorcon E, generic
	fluocinolone acetonide	Cream, ointment (emollient base)	0.05	Synalar, generic
	fluocinonide	Cream	0.2	Lidex, generic
	halcinonide	Cream, gel, ointment	0.05	Halog
	triamcinolone acetonide	Cream, ointment Cream, ointment	0.1 0.5	Kenalog, generic Kenalog, generic
III, Medium	betamethasone dipropionate	Lotion	0.05	Maxivate, generic
	betamethasone valerate	Cream	0.1	Beta-Val, generic
	clocortolone pivalate	Cream	0.1	Cloderm
	desoximetasone	Cream	0.05	Topicort LP, generic
	flurandrenolide	Cream, ointment	0.025	Cordran SP (cream)
	fluticasone propionate	Cream, ointment,	0.05	Cutivate, generic
	hydrocortisone butyrate	Tape	4 mcg/cm²	Locoid, generic
	mometasone furoate	Cream	0.05	Elocon, generic
	triamcinolone acetonide	Ointment Solution Cream, ointment Cream ointment, lotion Cream, ointment, lotion	0.1 0.2% 0.1 0.025 or 0.1 0.05	Kenalog, generic Aristocort Generic Generic Kenalog
IV, Low	alclometasone dipropionate	Cream, ointment	0.05	Aclovate, generic
	desonide	Cream	0.05	DesOwen, generic
	fluocinolone acetonide	Cream, solution	0.01	Synalar, generic
	hydrocortisone	Lotion	0.25	Generic
	hydrocortisone acetate	Cream, ointment, lotion Cream, ointment, lotion, solution Cream, ointment, lotion Cream, ointment	0.5 1 2.5 0.5, 1	Generic Generic Generic Cortef, Lanacort 10 Crème, generic

^∗Range: Group I (very potent) to Group IV (least potent). Note: Some of the drugs appear in more than one category.

The most common complication is suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which usually is not associated with symptoms until the corticosteroid is stopped.

Therapeutic Overview of Topical Corticosteroids

Toxicity to topical corticosteroids, although not common, is the same as the toxicity that occurs when corticosteroids are given systemically. Other common adverse effects include atrophy, striae, telangiectasia, purpura, acne, perioral dermatitis, and steroid rosacea. Glaucoma and cataracts may develop after prolonged use of corticosteroids around the eyes. The risk of side effects is increased when topical corticosteroids are used over a prolonged time, under occlusion, on the face, and on intertriginous locations.

Mechanism of Action

Topical corticosteroids diffuse across cell membranes and induce cutaneous vasoconstriction commensurate with their potency. This results in a local antiinflammatory effect. The topical route is elected when a local effect is preferred to the systemic effect produced by the same product given orally. Topical corticosteroids inhibit the migration of macrophages and leukocytes into the area by reversing vascular dilation and permeability of small vessels in the upper dermis. See Chapter 51 for further information.

• Group I corticosteroids are used for severe dermatoses over nonfacial/nonintertriginous areas such as psoriasis, severe atopic dermatitis, or severe contact dermatitis. They are especially useful over the palms and soles, which tend to resist topical corticosteroid penetration because of skin thickness.

• Preparations of intermediate to potent strength are appropriate for mild to moderate nonfacial/nonintertriginous dermatoses.

• Eyelid and genital dermatoses should be treated with topical corticosteroids of mild strength.

• Preparations of mild to intermediate strength should be considered when large areas are treated because of the likelihood of systemic absorption.

• Treatment should be discontinued when the skin condition has resolved. Tapering the corticosteroid will prevent recurrence of the skin condition. Tapering is best performed by gradually reducing the potency and dosing frequency at 2-week intervals.

• Therapy may be continued for chronic diseases that are responsive to treatment; patients should be monitored for the development of adverse effects and/or tachyphylaxis (rapid development of a decreased response).

• Generic topical corticosteroids are effective for treatment of most skin disorders in the primary care setting. Generic medications often have slightly less potency or vehicles that are less cosmetically appealing, but the substantial cost savings may offset any differences in efficacy or feel.

Pharmacologic Treatment

Topical corticosteroids are ranked according to potency, with group I as the most potent and group VII as the least potent. It is usually sufficient to divide them into high-, medium-, and low-potency groups. Frequently, weaker strengths are used because they are considered to be safer. However, adequate strength is necessary for a therapeutic response. Weak OTC hydrocortisone is not effective against many dermatoses; a medium-strength steroid from class III or IV is often more effective. If the patient does not respond, treatment should be reevaluated.

Potency is the most important variable when a topical steroid corticosteroid is selected. A drug from each potency level should be chosen to meet the prescriptive needs of the patient. The potency of a steroid is not determined by its strength but by vasoconstrictor assays.

The dose of one corticosteroid does not correlate with the dose of another—that is, diflorasone diacetate (Psorcon) ointment 0.05% is much stronger than hydrocortisone 2.5%.

Vasoconstrictor assays measure skin blanching when an agent is applied to skin under occlusion. A difference in potency may be noted between generic and name brand corticosteroid equivalents. Pharmacists are allowed to substitute generic drugs unless the health care provider requests “No substitutions” or “Brand necessary.”

Use low-potency agents in children, on large areas, for mild conditions, and on body sites that are especially prone to corticosteroid damage, such as the face, scrotum, axilla, flexures, and skin folds.

Steroids that are potent are corticosteroids used for severe conditions or on a small area of the body.

Reserve high-potency agents for areas and conditions that are resistant to treatment with milder agents; these may be alternated with milder agents. Short-term intermittent therapy with the use of high-potency agents may be more effective and may cause fewer adverse effects than continuous treatment with low-potency agents. No fluorinated or high-potency corticosteroid should be used on the face.

For all groups, apply the product sparingly two to four times a day. Adequate results are usually achieved with twice-a-day application and a course of therapy of 2 to 6 weeks. To prevent rebound, do not discontinue treatment abruptly after long-term use of a potent agent. Instead, reduce the frequency of application, or use a lower-potency agent.

When desired results are not achieved, stop therapy for 4 to 7 days, and then resume treatment with a different agent. A more potent corticosteroid may be needed.

A drug from each potency level should be chosen to meet the prescriptive needs of the provider. Triamcinolone is commonly used because it is available generically and comes in a variety of strengths. Triamcinolone 0.5% is a good product of medium strength that is effective for many rashes seen in the office setting.

Group I

Topical corticosteroids in group I are super-potent agents. The amount of drug applied to the body per day and the duration of treatment must be carefully monitored. Per week, a maximum of 50 g of cream or ointment should be used. The duration of daily use of super-potent topical corticosteroids should not exceed 2 weeks, if possible. A period of 1 week is needed before a group I topical corticosteroid can be used again. This is called cyclic or pulse dosing. Diflorasone diacetate can be used under occlusion; betamethasone dipropionate cannot. Occlusive dressings should be used for no longer than 12 hours at a time. Renal suppression, skin atrophy, and other side effects are possible. Patients who use group I topical corticosteroids should be monitored closely for HPA suppression. Prescriptions should limit refills.

Group II

These are also considered high-potency corticosteroids. The risk of adverse effects is reduced if these agents are used for less than 6 to 8 weeks, except on the face or areas where opposing skin surfaces touch (e.g., skin folds of the groin, axillae, and breasts).

Groups III Through V

These are considered preparations of medium potency. They are the most commonly indicated preparations for skin conditions for which prescription strength corticosteroids are required. They often have different chemical bases. Treatment duration should not exceed 8 weeks (see previous section on group II).

Groups VI and VII

These preparations of low potency are useful for covering large areas. Group VII agents are generally OTC preparations that are not strong enough to treat many conditions.

How to Monitor

• Reevaluate after about 10 days to determine whether the condition is responding to treatment.

• Monitor for superinfection.

• High-potency topical corticosteroids may require periodic evaluation of HPA axis suppression with the use of morning plasma cortisol, urinary free cortisol, and adrenocorticotropic hormone (ACTH) stimulation tests. If evidence of HPA axis suppression is noted, the health care provider should attempt to withdraw the topical corticosteroid very gradually. Decrease the number of applications or change to the use of a less-potent corticosteroid to begin withdrawing the corticosteroid from the patient.

• Children, in comparison with adults, have a larger skin surface area–to–body weight ratio. They may be more susceptible to topical corticosteroid–induced HPA axis suppression and Cushing’s syndrome. In children, symptoms of HPA may include linear growth retardation, delayed weight gain, and low cortisol levels.

• The least-potent corticosteroid that is compatible with effective treatment should be used.

• Potent corticosteroids should not be used to treat diaper dermatoses.

• Children younger than 12 years of age generally should not be treated with group I or II topical corticosteroids.

Pregnancy and Lactation

• Category C: No reports have described congenital anomalies or adverse effects associated with the use of corticosteroids during pregnancy. The use of group I through III corticosteroids in large amounts and with occlusive dressings for long periods of time has been shown to cause fetal abnormalities in animals, although none have been documented in humans.

• There is a significant association of fetal growth restriction with maternal exposure to potent/very potent topical corticosteroids, but not with mild/moderate topical corticosteroids.

• Effects on lactation are not known.

• Corticosteroids absorbed systemically can be detected in breast milk in quantities that are not likely to affect the infant.

• Use with caution.

• These drugs should not be applied to the nipples prior to nursing.

• Primary bacterial infection, such as impetigo, acne, erysipelas, cellulitis, rosacea, or perioral dermatitis

Warnings

HPA axis suppression has occurred. Limit the amount, potency, and length of treatment.

Precautions

• Very high-potency or high-potency agents should not be used on the face, under the arms, or in the groin area.

• Care should be taken when applying topical corticosteroid to the eyelids or around the eyes because it may get into the eyes.

• With prolonged use, corticosteroids may cause steroid-induced glaucoma or cataracts.

• Local irritation may develop; discontinue use.

• Skin atrophy is common with higher potency and longer duration of treatment.

• Psoriasis: Do not use as sole therapy in widespread plaque psoriasis.

• Infection: Treating skin infection with topical corticosteroids can worsen the infection.

Pharmacokinetics

• Corticosteroids are absorbed through the skin.

• Time to peak concentration is 12 to 24 hours.

• Corticosteroids are protein bound, metabolized by the liver, and excreted in urine and bile.

Adverse Effects

Local

• Itching, burning, erythema, folliculitis, perioral dermatitis, acneiform eruption, dry skin, allergic contact dermatitis, maceration, secondary infection, skin atrophy striae, and telangiectasia. Use of topical corticosteroids under occlusion may cause these adverse effects more frequently.

• With reduction or discontinuation of potent topical corticosteroids, chronic plaque psoriasis may develop into pustular psoriasis. To prevent rebound effects, long-term or potent topical corticosteroids should be discontinued gradually or the patient switched to a less-potent corticosteroid to facilitate withdrawal.

Systemic

• Reversible HPA axis suppression may be induced by topical corticosteroids.

• Symptoms of Cushing’s syndrome, hyperglycemia, and glycosuria may be induced.

Overdosage

• Topical corticosteroids are absorbed systemically in quantities sufficient to produce systemic complications.

Immunosuppressive Drugs

Specific Drugs

pimecrolimus (Elidel), tacrolimus (Protopic)

Indications

• Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients who are at least 2 years old

Mechanism of Action

• Calcineurin inhibitor; blocks production of proinflammatory cytokines by T-lymphocytes and prevents release of inflammatory mediators from cutaneous mast cells and basophils

• Less likely than topical corticosteroids to cause systemic immunosuppression

• Does not cause skin atrophy

Warnings

• Black box warnings for potential risk of cancer (skin malignancies and lymphoma) have been issued with this class of drugs. Based on data from animal studies, the case reports, and the pharmacology, these agents may increase the patient’s risk of developing cancer. Although this risk is uncertain, the FDA advisory emphasizes that use of these products should strictly follow each product’s labeling.

• Long-term safety (longer than 1 year) unknown

• Do not use Elidel pimecrolimus (Elidel) in children younger than 2 years of age because its effect on immune system development is unknown.

Precautions

An FDA-approved medication guide must be given to the patient when an outpatient prescription (new or refill) is dispensed if the medication is to be used without direct supervision by a health care provider. Medication guides are available at www.fda.gov/cder/Offices/ODS/medication_guides.htm.

Pharmacokinetics

• Minimally absorbed through the skin, even when applied to large areas of inflamed skin

Pimecrolimus permeates skin at a lower rate than tacrolimus.

Adverse Effects

• Transient local irritation with mild to moderate burning, warmth, stinging, itching, and erythema

Dosage and Administration

• Topical calcineurin agents are considered second-line agents in the treatment of atopic dermatitis/eczema. They should be limited to use in patients who have failed treatment with other therapies.

• Apply twice daily until resolved. Do not use with occlusive dressings.

Antiinfectives

Topical Antibiotics

Mupirocin is the only drug in this class that is used exclusively for topical infection, and it is the only one discussed here in detail. Mupirocin represents a major advance because it allows topical treatment of impetigo. Bacitracin is very effective for most topical infections. Triple antibiotic ointments vary in their composition; usually, they contain neomycin, which causes a greater number of allergic reactions than are produced by other topical agents. See Chapter 58 for information on other drugs in this class.

• Systemic antibiotics are needed for diffuse impetigo, cellulitis, and other more-than-superficial infections. Apply gauze dressing if indicated.

• Treatment should be reevaluated if no improvement is seen in 3 to 5 days (Table 13-3).

TABLE 13-3

Important Characteristics of Topical Antibiotics

Antibiotic	Effective Against	Formulation	Administration
mupirocin	Gram positive	2% cream, ointment	tid
bacitracin	Gram positive	500 units/g ointment	daily to qid
erythromycin	Gram positive	0.5% (ophthalmic), 2% ointment; 2% gel	bid/tid
gentamicin	Gram negative	0.3% ointment (ophthalmic); 0.1% ointment, cream	tid or qid
neomycin	Gram negative	3.5, 5 mg/g ointment; 3.5 mg/g cream	tid
polysporin with neomycin and bacitracin	Gram negative	5000 or 10,000 units/g cream, ointment	tid
retapamulin	Gram positive, anaerobes	1% ointment	bid